1210-33-9

Basic information

• Product Name: DIBENZOSUBERYL CHLORIDE
• Synonyms: d)cycloheptene,10,11-dihydro-5-chloro-5h-dibenzo(;5-CHLORO-10,11-DIHYDRO-5H-DIBENZO[A,D]CYCLOHEPTENE;5-CHLORODIBENZOSUBERANE;DIBENZOSUBERYL CHLORIDE;5-Chlorodibenzosuberane~5-Chloro-10,11-dihydro-5H-dibenzo[a,d]cycloheptene;5-CHLOROBENZOSUBERANE;10,11-Dihydro-5-chloro-5H-dibenzo[a,d]cycloheptene;5-Chloro-2,3:6,7-dibenzosuberane
• CAS NO: 1210-33-9
• Molecular Formula: C₁₅H₁₃Cl
• Molecular Weight: 228.72
• EINECS: 214-910-2
• Product Categories: Protection & Derivatization Reagents (for Synthesis);Synthetic Organic Chemistry;Alkyl;Building Blocks;Chemical Synthesis;Halogenated Hydrocarbons;Organic Building Blocks
• Mol File: 1210-33-9.mol
• Article Data: 9

Chemical Properties

• Melting Point: 106-107 °C(lit.)
• Boiling Point: 321.7°Cat760mmHg
• Flash Point: 136.6°C
• Appearance: /
• Density: 1.19g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• Sensitive: Moisture Sensitive
• Stability: Light Sensitive
• BRN: 612280
• CAS DataBase Reference: DIBENZOSUBERYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DIBENZOSUBERYL CHLORIDE(1210-33-9)
• EPA Substance Registry System: DIBENZOSUBERYL CHLORIDE(1210-33-9)

Safety Data

• Hazard Codes: 34:
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: 3261
• WGK Germany: 3
• RTECS: HO8302000
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 1210-33-9(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1210-33-9 differently. You can refer to the following data:
1. Reagent for introduction of the 5-dibenzosuberyl moiety as a modulator for anticancer drugs.1
2. Dibenzosuberyl Chloride is used in the synthesis of atypical tricyclic antidepressant as well as dibenzosuberyl-substituted tropines as ligands for acetylcholine-binding protein. Dibenzosuberyl Chlori de is also used in the preparation of amino protecting group for solid phase peptide synthesis.
3. Dibenzosuberyl Chloride is used in the synthesis of atypical tricyclic antidepressant as well as dibenzosuberyl-substituted tropines as ligands for acetylcholine-binding protein. Dibenzosuberyl Chloride is also used in the preparation of amino protecting group for solid phase peptide synthesis.

InChI:InChI=1/C15H13Cl/c16-15-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)15/h1-8,15H,9-10H2

Upstream product

• 4890-85-1 o-phenethylbenzoic acid 
• 1210-35-1 10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-one 
• 1210-34-0 dibenzosuberol 

Downstream Products

• 59188-82-8 N-Dibenzosuberyl-2-(4-methoxyphenyl)-ethylamin 
• 4821-67-4 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N,N-dimethyl-aniline 
• 68101-79-1 [4-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylamino)-phenyl]-acetonitrile 
• 68101-80-4 (2,6-Diethyl-phenyl)-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-amine 
• 68101-77-9 (10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(2-ethyl-6-methyl-phenyl)-amine 
• 68101-82-6 2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylamino)-3-methyl-benzoic acid methyl ester 
• 68101-81-5 (10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(2,6-diisopropyl-phenyl)-amine 
• 68101-76-8 (10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(2,6-dimethyl-phenyl)-amine 
• 68101-78-0 (10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-(2-methoxy-6-methyl-phenyl)-amine 
• 439093-87-5 C₂₇H₂₃ClN₄O₅S 
• 439093-84-2 C₂₇H₂₃N₅O₇S 
• 439093-43-3 C₂₇H₂₇N₅O₇S 
• 7199-29-3 Cyheptamide 
• 69159-50-8 1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine 

Relevant articles and documents

New compounds: amides derived from ((10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl) thio)acetic acid.

-

Dibenzo[b,f][1,4]oxazepines and dibenzo[b,e]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H1R, H4R, 5-HT2AR and other selected GPCRs

Inspired by VUF6884 (7-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine), reported as a dual H1/H4 receptor ligand (pKi: 8.11 (human H1R (hH1R)), 7.55 (human H4R (hH4R))), four known and 28 new oxazepine and related oxepine derivatives were synthesised and pharmacologically characterized at histamine receptors and selected aminergic GPCRs. In contrast to the oxazepine series, within the oxepine series, the new compounds showed high affinity to the hH1R (pKi: 6.8–8.7), but no or moderate affinity to the hH4R (pKi: ≤ 5.3). For one oxepine derivative (1-(2-Chloro-6,11-dihydrodibenzo[b,e]oxepin-11-yl)-4-methylpiperazine), the enantiomers were separated and the R-enantiomer was identified as the eutomer at the hH1R (pKi: 8.83 (R), 7.63 (S)) and the guinea-pig H1R (gpH1R) (pKi: 8.82 (R), 7.41 (S)). Molecular dynamic studies suggest that the tricyclic core of the compounds is bound in a similar mode into the binding pocket, as described for doxepine in the hH1R crystal structure. Moreover, docking studies of all oxepine derivatives at the hH1R indicate that the oxygen and the position of the chlorine in the tricyclic core determines, if the R- or the S-enantiomer is the eutomer. For some of the oxazepines and oxepines the affinity to other aminergic GPCRs is in the same range as to hH1R or hH4R, thus, those compounds have to be classified as dirty drugs. However, one oxazepine derivative (3,7-Dichloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine was identified as dual hH1/h5-HT2A receptor ligand (pKi: 9.23 (hH1R), 8.74 (h5-HT2AR), ≤7 at other analysed GPCRs), whereas one oxepine derivative (1-(3,8-Dichloro-6,11-dihydrodibenzo[b,e]oxepin-11-yl)-4-methylpiperazine) was identified as selective hH1R antagonist (pKi: 8.44 (hH1R), ≤6.7 at other analyzed GPCRs). Thus, the pharmacological results suggest that the oxazepine/oxepine moiety and additionally the chlorine substitution pattern toggles receptor selectivity and specificity.

Anti-viral method

PCT No. PCT/US97/07431 Sec. 371 Date Jan. 6, 1999 Sec. 102(e) Date Jan. 6, 1999 PCT Filed May 2, 1997 PCT Pub. No. WO97/41846 PCT Pub. Date Nov. 13, 1997The present invention provides compounds which inhibit an envelope virus by inhibiting the fusion of the virus with the host cell. The virus may be inhibited in an infected cell, a cell susceptible of infection or a mammal in need thereof.